Source link : https://newshealth.biz/health-news/osimertinib-os-benefit-persists-in-nsclc/
Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), according to the latest results from the pivotal phase 3 LAURA study. “This updated analysis…demonstrates an improved favorable trend for overall survival benefit with […]
The post Osimertinib OS Benefit Persists in NSCLC first appeared on News Health.
Author : News Health
Publish date : 2025-03-31 10:40:00
Copyright for syndicated content belongs to the linked Source.